A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma. (NCT06393738)
A Phase 1 First in Human Study of ARV-393 in Adult Participants With Advanced Non-Hodgkin's Lymphoma
🩺 Plain-English Summary (8th-Grade Level)
This clinical trial is studying the safety and potential anti-tumor activity of an investigational drug called ARV-393 in patients diagnosed with advanced Relapsed/Refractory non-Hodgkin's lymphoma (R/R NHL) to determine if ARV-393 may be a possible treatment option. ARV-393 is thought to work by breaking down a protein present in many types of non-Hodgkins lymphomas, which may prevent, slow or stop tumor growth. This is the first time ARV-393 will be used by people. The investigational drug will be given as an oral tablet.
Who can join: Review the eligibility criteria below.
Location: Clinical Trial Site — New Haven, Connecticut
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (19 Sites)
- Clinical Trial Site — New Haven, Connecticut
- Clinical Trial Site — Miami, Florida
- Clinical Trial Site — Detroit, Michigan
- Clinical Trial Site — New Brunswick, New Jersey
- Clinical Trial Site — New York, New York
- Clinical Trial Site — New York, New York
- Clinical Trial Site — Cleveland, Ohio
- Clinical Trial Site — Nashville, Tennessee
- Clinical Trial Site — Houston, Texas
- Clinical Trial Site — Charlottesville, Virginia
- Clinical Trial Site — Toronto, Ontario
- Clinical Trial Site — Montreal, Quebec
- Clinical Trial Site — Copenhagen,
- Clinical Trial Site — Odense C,
- Clinical Trial Site — El Palmar, Murcia
- Clinical Trial Site — Pamplona, Navarre
- Clinical Trial Site — Barcelona,
- Clinical Trial Site — Madrid,
- Clinical Trial Site — Salamanca,
📞 Contact the Study Coordinator
Phone: (475) 345-0791
Email: clinicaltrialsARV-393@arvinas.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
Explore by condition: All Relapsed/Refractory (R/R) Mature B Cell Non Hodgkin Lymphoma (NHL) clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.